Entering text into the input field will update the search result below

Revive Therapeutics to explore bucillamine for COVID-19

  • Revive Therapeutics (OTCQB:RVVTF) is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases, including influenza and COVID-19.
  • The company has applied for a provisional patent with the USPTO, entitled “Use of Bucillamine in the Treatment of Infectious Diseases”.
  • Bucillamine is a disease-modifying anti-rheumatic drug marketed in Japan and South Korea for the treatment of rheumatoid arthritis.

Recommended For You

More Trending News

About RVVTF Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RVVTF--
Revive Therapeutics Ltd.